Campbell, Timothy B.
Harvard University · University of California, San Francisco · VA Boston Healthcare System · Massachusetts General Hospital · Bristol-Myers Squibb (United States) · Dana-Farber Cancer Institute · Harold C. Simmons Comprehensive Cancer Center · The University of Texas Southwestern Medical Center · Icahn School of Medicine at Mount Sinai
2 papers on CoChatORCID 0000-0002-3538-8784
Most cited papers
- Verified
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., et al. (2021) · New England Journal of Medicine
CAR-T cell therapy researchMultiple Myeloma Research and Treatments
Cited by 2,560
- Verified
Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma.
Raje, N., Berdeja, J., Lin, Y., Siegel, D., Jagannath, S., Madduri, D., Liedtke, M., Rosenblatt, J., Maus, M. V., Turka, A., et al. (2019) · New England Journal of Medicine
CAR-T cell therapy researchMultiple Myeloma Research and Treatments
Cited by 1,730
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free